385 related articles for article (PubMed ID: 34433637)
1. Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell-cold solid tumors.
Belmontes B; Sawant DV; Zhong W; Tan H; Kaul A; Aeffner F; O'Brien SA; Chun M; Noubade R; Eng J; Ma H; Muenz M; Li P; Alba BM; Thomas M; Cook K; Wang X; DeVoss J; Egen JG; Nolan-Stevaux O
Sci Transl Med; 2021 Aug; 13(608):. PubMed ID: 34433637
[TBL] [Abstract][Full Text] [Related]
2. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer.
Stieglmaier J; Benjamin J; Nagorsen D
Expert Opin Biol Ther; 2015; 15(8):1093-9. PubMed ID: 25971805
[TBL] [Abstract][Full Text] [Related]
3. CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic Cancer.
Xu Y; Fu J; Henderson M; Lee F; Jurcak N; Henn A; Wahl J; Shao Y; Wang J; Lyman M; Funes V; Espinoza B; Zhang R; Washington I; Chen SY; Zlomke H; Wang J; Niu N; Li P; Meng F; Burns W; Friedrich M; Stienen S; Bailis JM; Zheng L
Gastroenterology; 2023 Nov; 165(5):1219-1232. PubMed ID: 37507075
[TBL] [Abstract][Full Text] [Related]
4. LILRB1 Blockade Enhances Bispecific T Cell Engager Antibody-Induced Tumor Cell Killing by Effector CD8
Kim A; Han CJ; Driver I; Olow A; Sewell AK; Zhang Z; Ouyang W; Egen JG; Yu X
J Immunol; 2019 Aug; 203(4):1076-1087. PubMed ID: 31253728
[TBL] [Abstract][Full Text] [Related]
5. The Biodistribution of a CD3 and EpCAM Bispecific T-Cell Engager Is Driven by the CD3 Arm.
Suurs FV; Lorenczewski G; Stienen S; Friedrich M; de Vries EGE; de Groot DJA; Lub-de Hooge MN
J Nucl Med; 2020 Nov; 61(11):1594-1601. PubMed ID: 32284393
[TBL] [Abstract][Full Text] [Related]
6. Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3.
Schlereth B; Kleindienst P; Fichtner I; Lorenczewski G; Brischwein K; Lippold S; da Silva A; Locher M; Kischel R; Lutterbüse R; Kufer P; Baeuerle PA
Cancer Immunol Immunother; 2006 Jul; 55(7):785-96. PubMed ID: 16187083
[TBL] [Abstract][Full Text] [Related]
7. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
8. A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
Robinson HR; Qi J; Cook EM; Nichols C; Dadashian EL; Underbayev C; Herman SEM; Saba NS; Keyvanfar K; Sun C; Ahn IE; Baskar S; Rader C; Wiestner A
Blood; 2018 Aug; 132(5):521-532. PubMed ID: 29743179
[TBL] [Abstract][Full Text] [Related]
9. Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect
Zhong L; Shi W; Gan L; Liu X; Huo Y; Wu P; Zhang Z; Wu T; Peng H; Huang Y; Zhao Y; Yuan Y; Deng Z; Tang H
Theranostics; 2021; 11(13):6393-6406. PubMed ID: 33995664
[No Abstract] [Full Text] [Related]
10. Visualizing Spatial and Stoichiometric Barriers to Bispecific T-Cell Engager Efficacy.
You R; Artichoker J; Ray A; Gonzalez Velozo H; Rock DA; Conner KP; Krummel MF
Cancer Immunol Res; 2022 Jun; 10(6):698-712. PubMed ID: 35413104
[TBL] [Abstract][Full Text] [Related]
11. Microenvironment-responsive anti-PD-L1 × CD3 bispecific T-cell engager for solid tumor immunotherapy.
Liu D; Bao L; Zhu H; Yue Y; Tian J; Gao X; Yin J
J Control Release; 2023 Feb; 354():606-614. PubMed ID: 36669532
[TBL] [Abstract][Full Text] [Related]
12. The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types.
Einsele H; Borghaei H; Orlowski RZ; Subklewe M; Roboz GJ; Zugmaier G; Kufer P; Iskander K; Kantarjian HM
Cancer; 2020 Jul; 126(14):3192-3201. PubMed ID: 32401342
[TBL] [Abstract][Full Text] [Related]
13. Harnessing T cells to fight cancer with BiTE® antibody constructs--past developments and future directions.
Klinger M; Benjamin J; Kischel R; Stienen S; Zugmaier G
Immunol Rev; 2016 Mar; 270(1):193-208. PubMed ID: 26864113
[TBL] [Abstract][Full Text] [Related]
14. Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs.
Brozy J; Schlaepfer E; Mueller CKS; Rochat MA; Rampini SK; Myburgh R; Raum T; Kufer P; Baeuerle PA; Muenz M; Speck RF
J Virol; 2018 Jul; 92(14):. PubMed ID: 29720517
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) Molecule.
Pham E; Friedrich M; Aeffner F; Lutteropp M; Mariano NF; Deegen P; Dahlhoff C; Vogel F; Bluemel C; Harrold JM; Brandl C; Grinberg N; Rattel B; Coxon A; Bailis JM
Mol Cancer Ther; 2021 Oct; 20(10):1977-1987. PubMed ID: 34376583
[TBL] [Abstract][Full Text] [Related]
16. An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.
Ishiguro T; Sano Y; Komatsu SI; Kamata-Sakurai M; Kaneko A; Kinoshita Y; Shiraiwa H; Azuma Y; Tsunenari T; Kayukawa Y; Sonobe Y; Ono N; Sakata K; Fujii T; Miyazaki Y; Noguchi M; Endo M; Harada A; Frings W; Fujii E; Nanba E; Narita A; Sakamoto A; Wakabayashi T; Konishi H; Segawa H; Igawa T; Tsushima T; Mutoh H; Nishito Y; Takahashi M; Stewart L; ElGabry E; Kawabe Y; Ishigai M; Chiba S; Aoki M; Hattori K; Nezu J
Sci Transl Med; 2017 Oct; 9(410):. PubMed ID: 28978751
[TBL] [Abstract][Full Text] [Related]
17. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.
Wing A; Fajardo CA; Posey AD; Shaw C; Da T; Young RM; Alemany R; June CH; Guedan S
Cancer Immunol Res; 2018 May; 6(5):605-616. PubMed ID: 29588319
[TBL] [Abstract][Full Text] [Related]
18. Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma.
Gardell JL; Matsumoto LR; Chinn H; DeGolier KR; Kreuser SA; Prieskorn B; Balcaitis S; Davis A; Ellenbogen RG; Crane CA
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33122397
[TBL] [Abstract][Full Text] [Related]
19. CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation.
Gao J; Wang Z; Jiang W; Zhang Y; Meng Z; Niu Y; Sheng Z; Chen C; Liu X; Chen X; Liu C; Jia K; Zhang C; Liao H; Jung J; Sung E; Chung H; Zhang JZ; Zhu AX; Shen L
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37364935
[TBL] [Abstract][Full Text] [Related]
20. IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody.
Li J; Ybarra R; Mak J; Herault A; De Almeida P; Arrazate A; Ziai J; Totpal K; Junttila MR; Walsh KB; Junttila TT
Clin Cancer Res; 2018 Dec; 24(24):6447-6458. PubMed ID: 29950350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
